The construction of OOO B-PHARM’s first pharmaceutical plant is soon to be completed in the Vorsino Industrial Park (Kaluga Region). In September 2022, it is planned to launch here the production of 17 of the 27 medicines that are included in the company’s drug portfolio.
The foundation of the future enterprise was laid in May 2019, and on December 6, 2021, a license for the production of medicines for human use was obtained. The construction lasted 2.5 years.
The first phase of production will have been launched before July 2022. The production will start with the company’s most in-demand drugs (injectables in the form of injection solutions and lyophilizates): Meloxicam, Bitrigam, and Famotidine.
The estimated production capacity of the new plant is 20 million packages per year, with the possibility of expansion and modification of production. The new B-PHARM entreprise is going to become a member of the Kaluga pharmaceutical cluster.
The production building consists of a site for the production of medicines in vials, a site for the production of medicines in ampoules, a state-of-the-art physico-chemical laboratory, and an administrative block with technical premises.
The production complex has to undergo certification for GMP compliance in the first quarter of 2022.
According to the plan, the production of biotechnological medicines and organ-based preparations is to be launched in 2023.
